TRCT
LXEO icon

Tower Research Capital (TRC)’s Lexeo Therapeutics LXEO Stock Holding History

Tower Research Capital (TRC)’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Sell
5,237
-4,248
-45% -$23K ﹤0.01% 3373
2026
Q1 		$54.4K Buy
9,485
+8,659
+1,048% +$61.4K ﹤0.01% 2670
2025
Q4 		$8.2K Sell
826
-2,911
-78% -$26.6K ﹤0.01% 3963
2025
Q3 		$24.8K Sell
3,737
-1,357
-27% -$6.56K ﹤0.01% 3106
2025
Q2 		$20.5K Sell
5,094
-771
-13% -$2.54K ﹤0.01% 3668
2025
Q1 		$20.4K Buy
5,865
+4,210
+254% +$18.6K ﹤0.01% 2944
2024
Q4 		$10.9K Buy
1,655
+238
+17% +$1.88K ﹤0.01% 3768
2024
Q3 		$12.8K Sell
1,417
-158
-10% -$1.88K ﹤0.01% 3561
2024
Q2 		$25.3K Buy
1,575
+1,068
+211% +$15.5K ﹤0.01% 3614
2024
Q1 		$7.95K Sell
507
-983
-66% -$15.4K ﹤0.01% 4108
2023
Q4 		$20K Buy
+1,490
New +$18.5K ﹤0.01% 3646

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tower Research Capital (TRC)'s LXEO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Lexeo Therapeutics (LXEO) stake by 45% in Q2 2026, selling an estimated $23K and leaving 5,237 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

Tower Research Capital (TRC) first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $54.4K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Tower Research Capital (TRC) held 5,237 shares of Lexeo Therapeutics worth $24.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,248 Lexeo Therapeutics shares in Q2 2026, an estimated $23K.
  • Lexeo Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3373 holding.
  • Tower Research Capital (TRC) first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Lexeo Therapeutics position peaked at $54.4K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.